Equity

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Equity

Share Repurchases

In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2 million and 3.6 million shares of our common stock at a cost of approximately $250.0 million and $750.0 million during the three and nine months ended September 30, 2022, respectively. During the three and nine months ended September 30, 2021, we repurchased and retired approximately 2.2 million and 6.0 million shares of our common stock at a cost of approximately $750.0 million and $1.8 billion, respectively. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2022.

Accumulated Other Comprehensive Income (Loss)

The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:

(In millions)	Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax		Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax		Gains (Losses) on Net Investment Hedges, Net of Tax(1)		Unrealized gains (losses) on pension benefit obligation, Net of Tax		Currency Translation Adjustments		Total
Balance, December 31, 2021	$	(2.2)	$	53.8	$	25.5	$	(44.8)	$	(139.0)	$	(106.7)
Other comprehensive income (loss) before reclassifications	(26.4)		204.5		12.6		4.2		(154.5)		40.4
Amounts reclassified from accumulated other comprehensive income (loss)	7.4		(125.5)		(38.1)		—		58.9		(97.3)
Net current period other comprehensive income (loss)	(19.0)		79.0		(25.5)		4.2		(95.6)		(56.9)
Balance, September 30, 2022	$	(21.2)	$	132.8	$	—	$	(40.6)	$	(234.6)	$	(163.6)

(1) Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.

(In millions)	Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax		Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax		Gains (Losses) on Net Investment Hedges, Net of Tax		Unrealized gains (losses) on pension benefit obligation, Net of Tax		Currency Translation Adjustments		Total
Balance, December 31, 2020	$	1.4	$	(179.0)	$	(8.5)	$	(66.3)	$	(46.6)	$	(299.0)
Other comprehensive income (loss) before reclassifications	(2.5)		143.0		35.3		3.9		(80.3)		99.4
Amounts reclassified from accumulated other comprehensive income (loss)	1.1		62.0		(0.1)		—		—		63.0
Net current period other comprehensive income (loss)	(1.4)		205.0		35.2		3.9		(80.3)		162.4
Balance, September 30, 2021	$	—	$	26.0	$	26.7	$	(62.4)	$	(126.9)	$	(136.6)

The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):

(In millions)	Income Statement Location	Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)
		For the Three Months Ended September 30,				For the Nine Months Ended September 30,
		2022		2021		2022		2021
Gains (losses) on securities available for sale	Other (income) expense	$	(8.0)	$	(0.4)	$	(9.4)	$	(1.3)
	Income tax benefit (expense)	1.7		0.1		2.0		0.3
Gains (losses) on cash flow hedges	Revenue	77.7		(14.9)		143.2		(68.7)
	Operating expense	(0.8)		(0.3)		(3.5)		(0.3)
	Other (income) expense	—		—		(0.2)		0.1
	Income tax benefit (expense)	(7.8)		1.5		(14.0)		6.8
Gains (losses) on net investment hedges(1)	Other (income) expense	—		—		38.1		0.1
Currency Translation Adjustments	Other (income) expense	—		—		(58.9)		—
Total reclassifications, net of tax		$	62.8	$	(14.0)	$	97.3	$	(63.0)

(1) Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.